Eradication of Helicobacter pylori With Vonoprazan–Amoxicillin Dual Therapy as an Alternative for Bismuth‐Based Quadruple Therapy: A Systematic Review and Noninferiority Meta‐Analysis
Journal of Gastroenterology and Hepatology · 2026-09 · 41 (9) · 2545-2556
DOI: 10.1111/jgh.70565 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 11.07.2026. Verfasst von Pedro Robson Costa Passos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceará, Fortaleza, Ceará, Brazil. Hauptthemen laut MEDLINE: Sulfonamides, Helicobacter Infections, Helicobacter pylori, Pyrroles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Whether the efficacy of vonoprazan–amoxicillin dual therapy (VADT) for Helicobacter pylori eradication is clinically acceptable compared with guideline‐recommended bismuth‐based quadruple therapy (BQT) remains uncertain. Prior analyses have largely relied on superiority frameworks.
Methods
PubMed, EMBASE, and CENTRAL were searched through December 23, 2025, for randomized controlled trials (RCTs) comparing VADT with BQT for H. pylori eradication. Intention‐to‐treat and per‐protocol eradication were summarized through Bayesian meta‐analysis as absolute risk differences. Noninferiority margins were prespecified at −10%, −5%, and 0% (superiority). Adverse events (AEs) were evaluated as secondary outcomes. Evidence certainty was assessed using GRADE.
Results
Eighteen Asian RCTs (5866 participants) were included. In intention‐to‐treat analyses, VADT achieved an absolute eradication increase of +2.27% compared with BQT (95% credible interval [CrI] −1.34% to +5.71%). The posterior probability of noninferiority exceeded 99% for the −10% and −5% margins but declined to 90.41% at 0%. In per‐protocol analyses, eradication showed an absolute decrease of 0.28% (95% CrI −3.30% to +4.17%), with noninferiority probabilities exceeding 99% for the −10% and −5% margins, but declining to 56.43% at 0%. VADT was associated with significantly lower rates of dysgeusia, dizziness/headache, nausea/vomiting, and overall mild AEs. Evidence certainty was moderate for intention‐to‐treat noninferiority in Eastern populations and low or very low for all other Eastern and Western analyses.
Discussion
VADT may be a reasonable alternative in East Asian settings where tolerability or regimen simplicity is a priority, but evidence is insufficient to support generalization to Western or non‐Asian populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceará, Fortaleza, Ceará, Brazil.
- Núcleo de Biomedicina (NUBIMED), Universidade Federal do Ceará, Fortaleza, Ceará, Brazil.
- Instituto Alfa de Gastroenterologia, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
- Department of Gastroenterology and Hepatology, Hospital da Polícia Militar de Minas Gerais, Belo Horizonte, Brazil.
ORCID-Profile: Pedro Robson Costa Passos, Mariana Macambira Noronha, Guilherme Grossi Lopes Cançado
Zitieren
APA
Passos, P. R. C., Filho, V. O. C., Noronha, M. M., Maia, M. C. B., & Cançado, G. G. L. (2026). Eradication of Helicobacter pylori With Vonoprazan–Amoxicillin Dual Therapy as an Alternative for Bismuth‐Based Quadruple Therapy: A Systematic Review and Noninferiority Meta‐Analysis. Journal of Gastroenterology and Hepatology, 41(9), 2545-2556. https://doi.org/10.1111/jgh.70565
Vancouver
Passos PRC, Filho VOC, Noronha MM, Maia MCB, Cançado GGL. Eradication of Helicobacter pylori With Vonoprazan–Amoxicillin Dual Therapy as an Alternative for Bismuth‐Based Quadruple Therapy: A Systematic Review and Noninferiority Meta‐Analysis. Journal of Gastroenterology and Hepatology. 2026;41(9):2545-2556. doi:10.1111/jgh.70565
BibTeX
@article{Passos2026,
author = {Passos, Pedro Robson Costa and Filho, Valbert Oliveira Costa and Noronha, Mariana Macambira and Maia, Melissa Cortez Braga and Cançado, Guilherme Grossi Lopes},
title = {Eradication of Helicobacter pylori With Vonoprazan–Amoxicillin Dual Therapy as an Alternative for Bismuth‐Based Quadruple Therapy: A Systematic Review and Noninferiority Meta‐Analysis},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {9},
pages = {2545--2556},
doi = {10.1111/jgh.70565}
}
EUVIMED